What Orakl Oncology does

Orakl Oncology is a French precision oncology company founded in 2023 as a spin-off of Gustave Roussy, one of Europe's leading cancer research centers, headquartered at The Hive innovation campus in Villejuif. The company builds an AIxBio platform that combines a living biological layer of patient-derived tumor organoids with a proprietary multimodal dataset spanning matched drug responses, multi-omics, medical imaging, and longitudinal clinical histories. On top of this dataset, Orakl operates a first-in-class predictive engine that it reports achieving 90% accuracy in forecasting individual patient response to drug candidates across more than 30 clinical trials, alongside a discovery engine for novel therapeutic targets.

The company's commercial product surface is organized around two modules: O-Predict, a clinical trial success suite that anticipates endpoints (ORR, PFS, OS), identifies predictive biomarkers for patient stratification, surfaces synergistic drug combinations, and assesses benefit-risk profiles; and O-Target, a discovery engine that identifies high-potential therapeutic targets for first-in-class medicines. Initial therapeutic focus is on pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and KRAS-mutant cancers — indications where the company claims to operate the largest proprietary dataset of its kind.

Commercially, Orakl operates a B2B enterprise model selling predictive analytics and target discovery subscriptions and partnerships to biopharmaceutical companies through direct field sales. The company is pre-revenue or sub-$1M at the revenue line, having formally launched its commercial products only alongside its December 2024 €11M seed round led by Singular, and has raised approximately €14M to date across two seed rounds plus AWS infrastructure credit. The GTM motion depends on a global hospital network partnership program that feeds the organoid and data pipeline, with Gustave Roussy serving as the foundational institutional anchor.

Name

Orakl Oncology

Legal name

Orakl Oncology SAS

Website

https://orakl-oncology.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Orakl Oncology is a French AIxBio precision oncology company that combines patient-derived tumor organoids with multimodal data and predictive AI to help biopharmaceutical companies improve clinical trial success and discover novel cancer drug targets in PDAC, colorectal, and KRAS-mutant cancers.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372), Services-Medical Laboratories (8071)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)

Keywords

• Precision oncology platform
• AI drug discovery
• Tumor organoid screening
• Clinical trial prediction
• Biopharma partnerships

Headquarters

HQ city

Villejuif

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biopharma Partnerships and Licensing: Revenue generated through strategic partnerships with biopharmaceutical companies, offering O-Predict (clinical trial success prediction suite) and O-Target (therapeutic target identification) solutions. The company provides subscription-based access to their AIxBio platform and predictive engines for drug development applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Orakl Oncology builds and sells a native AIxBio engine for oncology drug development, combining patient-derived tumor organoids, a proprietary signal-rich multimodal dataset (drug responses, multi-omics, clinical data, imaging), and a first-in-class predictive AI model. It commercializes this through two solutions for biopharma partners: O-Predict, a clinical trial prediction suite that anticipates endpoints, identifies predictive biomarkers, and uncovers synergistic drug combinations; and O-Target, a discovery engine that identifies high-potential therapeutic targets for first-in-class medicines.

Product overview

Orakl Oncology offers a unified AIxBio platform built around three core components: (1) the AIxBio Engine as the foundational technology combining patient-derived organoids, a proprietary signal-rich multimodal dataset, and predictive modeling; (2) O-Predict, a clinical trial prediction module that forecasts patient responses and supports biomarker discovery; and (3) O-Target, a discovery engine for identifying novel therapeutic targets. The platform targets oncology drug development with initial focus on pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and KRAS-mutant cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• O-Predict O-Predict is a clinical trial prediction suite that enables biopharmaceutical R&D and clinical development teams to anticipate key clinical endpoints (ORR, PFS, OS), identify predictive biomarkers for patient stratification, uncover synergistic drug combinations, and assess benefit-risk profiles across treatment regimens. It is built on Orakl's AIxBio engine and is offered to biopharma partners as a subscription-based platform solution.
• O-Target O-Target is a discovery engine that identifies high-potential therapeutic targets, accelerating the development of next-generation first-in-class medicines. It is built on Orakl's AIxBio engine and is offered to biopharma partners as a subscription-based platform solution for pipeline prioritization and target identification.

Quantifiable outcome

• 90% accuracy in predicting individual patient response to new drug candidates
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Gustave RoussycoreStrategic or Co-development PartnerOrakl Oncology is a spin-off from Gustave Roussy, one of Europe's leading cancer research centers. The company maintains a strategic partnership with Gustave Roussy's global hospital network to build a continuously expanding collection of patient-matched multimodal data and living biological samples. This partnership provides access to real patient tumor samples and clinical data essential for organoid generation and platform validation.
• Global Hospital NetworkcoreStrategic or Co-development PartnerOrakl partners with a global network of hospitals to build a continuously expanding collection of patient-matched multimodal data and living biological samples. Together with hospital partners, they build unique, standardized multimodal datasets that power both drug development and academic research.
• Biopharmaceutical Companies (generic)coreStrategic or Co-development PartnerOrakl's discovery and predictive engines (O-Predict and O-Target) power smarter pipeline decisions and prioritization for biopharma partners. O-Predict supports clinical trial success by enabling teams to anticipate key clinical endpoints, identify predictive biomarkers, uncover synergistic drug combinations, and assess benefit-risk profiles. O-Target identifies high-potential therapeutic targets for next-generation first-in-class medicines.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Schrödinger: Computational chemistry and predictive modeling platform serving pharma R&D. Comparable in selling predictive software to biopharma, though Orakl differentiates with patient-derived organoid biology.
• ConcertAI: Real-world data and AI company for oncology, selling insights and predictive analytics to biopharma. Comparable in monetizing multimodal oncology data and predictive modeling for pharma R&D.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Like Orakl, Recursion combines biological experimentation with AI to predict drug behavior, but at vastly greater scale and with a broader indication footprint.
• Tempus Labs: AI-driven precision medicine company building large multimodal clinical and molecular datasets for oncology. Comparable in selling data-driven oncology insights to biopharma, with broader scale and a U.S. footprint.

Direct peers

• Owkin: AI precision medicine company leveraging multimodal patient data (multi-omics, imaging, clinical) from hospital networks to predict treatment outcomes. Highly comparable European AI-oncology peer with similar hospital-partnered data strategy.
• Valo Health: AI-powered drug discovery company combining patient data, lab experiments, and computation to accelerate oncology and other therapeutic programs. Comparable in combining biological data with AI for clinical prediction.
• Exscientia: AI-native pharma company focused on accelerating precision oncology and other drug discovery through patient-derived biology and AI. Closely comparable in mission, AI-first oncology positioning, and biopharma partnership model.
• Insitro: Machine-learning-driven drug discovery company combining induced pluripotent stem cell biology with AI/ML for target identification and drug development. Overlaps with Orakl on AI + patient-relevant biology for predictive modeling.

Emerging players

• Lantern Pharma: AI-driven precision oncology company using machine learning on genomic and clinical data to identify responders and accelerate oncology drug development. Comparable AI-oncology focus but with a more clinical-stage orientation.
• Notable Labs: AI-driven precision oncology company using patient-derived functional testing to predict patient response to cancer therapies. Highly comparable in combining patient-derived biology with AI to predict drug response.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/orakloncology
• Xx.com/orakldotbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orakl Oncology